Royalty Pharma plc (NASDAQ: RPRX) Stock Competitors & Peer Comparison
See RPRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RPRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RPRX | $56.93 | +0.30% | 24.9B | 10.71 | $5.25 | +1.63% |
| CORT | $121.19 | +1.33% | 12.8B | 338.69 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $79.78 | +2.33% | 6B | 81.19 | $0.97 | N/A |
| LQDA | $27.38 | +2.62% | 2.5B | 20.45 | $1.37 | N/A |
| PBH | $48.23 | +1.39% | 2.3B | 10.82 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $16.00 | +3.09% | 889.7M | -5.87 | -$2.52 | N/A |
| HELP | $11.80 | +12.27% | 664.5M | -2.57 | -$4.16 | N/A |
Stock Comparison
Corcept Therapeutics Incorporated (NASDAQ: CORT)
RPRX vs CORT Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, CORT has a market cap of 12.8B. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while CORT trades at $121.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas CORT's P/E ratio is 338.69. In terms of profitability, RPRX's ROE is +0.12%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RPRX is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
RPRX vs WBA Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas WBA's P/E ratio is -1.64. In terms of profitability, RPRX's ROE is +0.12%, compared to WBA's ROE of -0.57%. Regarding short-term risk, RPRX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
RPRX vs KNSA Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while KNSA trades at $79.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas KNSA's P/E ratio is 81.19. In terms of profitability, RPRX's ROE is +0.12%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, RPRX is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
RPRX vs LQDA Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, LQDA has a market cap of 2.5B. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while LQDA trades at $27.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas LQDA's P/E ratio is 20.45. In terms of profitability, RPRX's ROE is +0.12%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, RPRX is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
RPRX vs PBH Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while PBH trades at $48.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas PBH's P/E ratio is 10.82. In terms of profitability, RPRX's ROE is +0.12%, compared to PBH's ROE of +0.09%. Regarding short-term risk, RPRX is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
RPRX vs HROWL Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas HROWL's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, RPRX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
RPRX vs HROWM Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas HROWM's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, RPRX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
RPRX vs LTGO Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, LTGO has a market cap of 889.7M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while LTGO trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas LTGO's P/E ratio is -5.87. In terms of profitability, RPRX's ROE is +0.12%, compared to LTGO's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
RPRX vs HELP Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, HELP has a market cap of 664.5M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while HELP trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas HELP's P/E ratio is -2.57. In terms of profitability, RPRX's ROE is +0.12%, compared to HELP's ROE of -0.71%. Regarding short-term risk, RPRX is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
RPRX vs SVA Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas SVA's P/E ratio is -5.68. In terms of profitability, RPRX's ROE is +0.12%, compared to SVA's ROE of -0.01%. Regarding short-term risk, RPRX is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
RPRX vs CUVL Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, CUVL has a market cap of 281.4M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while CUVL trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas CUVL's P/E ratio is 12.04. In terms of profitability, RPRX's ROE is +0.12%, compared to CUVL's ROE of N/A. Regarding short-term risk, RPRX is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
RPRX vs CELG-RI Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, CELG-RI has a market cap of 233.9M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
RPRX vs HITI Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while HITI trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas HITI's P/E ratio is -9.53. In terms of profitability, RPRX's ROE is +0.12%, compared to HITI's ROE of -0.36%. Regarding short-term risk, RPRX is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check HITI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
RPRX vs ETRA Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, ETRA has a market cap of 193.9M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while ETRA trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas ETRA's P/E ratio is -3.45. In terms of profitability, RPRX's ROE is +0.12%, compared to ETRA's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ETRA's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
RPRX vs CTOR Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, CTOR has a market cap of 78.9M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while CTOR trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas CTOR's P/E ratio is -1.81. In terms of profitability, RPRX's ROE is +0.12%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, RPRX is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
RPRX vs ATLN Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas ATLN's P/E ratio is -0.68. In terms of profitability, RPRX's ROE is +0.12%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, RPRX is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ATLN's competition here
Rite Aid Corporation (NYSE: RAD)
RPRX vs RAD Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas RAD's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to RAD's ROE of +2.76%. Regarding short-term risk, RPRX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
RPRX vs GLTO Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas GLTO's P/E ratio is -1.78. In terms of profitability, RPRX's ROE is +0.12%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, RPRX is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
RPRX vs NSRX Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, NSRX has a market cap of 30.9M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while NSRX trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas NSRX's P/E ratio is -4.99. In terms of profitability, RPRX's ROE is +0.12%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, RPRX is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
RPRX vs SCYX Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, SCYX has a market cap of 26.5M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while SCYX trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas SCYX's P/E ratio is -1.23. In terms of profitability, RPRX's ROE is +0.12%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, RPRX is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
RPRX vs COSM Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, COSM has a market cap of 17.1M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while COSM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas COSM's P/E ratio is -0.43. In terms of profitability, RPRX's ROE is +0.12%, compared to COSM's ROE of -1.19%. Regarding short-term risk, RPRX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check COSM's competition here
Cerenome, Inc. (NASDAQ: CNSY)
RPRX vs CNSY Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, CNSY has a market cap of 12.3M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while CNSY trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas CNSY's P/E ratio is -0.43. In terms of profitability, RPRX's ROE is +0.12%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, RPRX is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
RPRX vs BFRI Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, BFRI has a market cap of 11.8M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while BFRI trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas BFRI's P/E ratio is -1.67. In terms of profitability, RPRX's ROE is +0.12%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, RPRX is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
RPRX vs CJJD Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas CJJD's P/E ratio is -0.46. In terms of profitability, RPRX's ROE is +0.12%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, RPRX is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
RPRX vs SSY Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas SSY's P/E ratio is -2.86. In terms of profitability, RPRX's ROE is +0.12%, compared to SSY's ROE of -0.09%. Regarding short-term risk, RPRX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
RPRX vs SCNX Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, SCNX has a market cap of 6.3M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while SCNX trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas SCNX's P/E ratio is -1.84. In terms of profitability, RPRX's ROE is +0.12%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, RPRX is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SCNX's competition here
POMDOCTOR Ltd (NASDAQ: POM)
RPRX vs POM Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while POM trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas POM's P/E ratio is -0.11. In terms of profitability, RPRX's ROE is +0.12%, compared to POM's ROE of +0.16%. Regarding short-term risk, RPRX is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
RPRX vs BGMS Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, BGMS has a market cap of 4.5M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while BGMS trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas BGMS's P/E ratio is -0.23. In terms of profitability, RPRX's ROE is +0.12%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BGMS's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
RPRX vs BFRIW Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, BFRIW has a market cap of 4.3M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while BFRIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas BFRIW's P/E ratio is -0.01. In terms of profitability, RPRX's ROE is +0.12%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, RPRX is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BFRIW's competition here
Eocene Ltd. (NASDAQ: EOCN)
RPRX vs EOCN Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, EOCN has a market cap of 3.8M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while EOCN trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas EOCN's P/E ratio is -0.26. In terms of profitability, RPRX's ROE is +0.12%, compared to EOCN's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
RPRX vs PAVS Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, PAVS has a market cap of 3.1M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while PAVS trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas PAVS's P/E ratio is -0.04. In terms of profitability, RPRX's ROE is +0.12%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, RPRX is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
RPRX vs MDVL Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas MDVL's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, RPRX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
RPRX vs ATNFW Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas ATNFW's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, RPRX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
RPRX vs BGMSP Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, RPRX's ROE is +0.12%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
RPRX vs AZNH Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas AZNH's P/E ratio is 38.35. In terms of profitability, RPRX's ROE is +0.12%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, RPRX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
RPRX vs LFLYW Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, RPRX's ROE is +0.12%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, RPRX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
RPRX vs PRPH Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, PRPH has a market cap of 140.2K. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas PRPH's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, RPRX is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
RPRX vs CPD Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, CPD has a market cap of 0. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas CPD's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CPD's ROE of N/A. Regarding short-term risk, RPRX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check CPD's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
RPRX vs ESRX Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas ESRX's P/E ratio is 10.69. In terms of profitability, RPRX's ROE is +0.12%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, RPRX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
RPRX vs IPXL Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas IPXL's P/E ratio is -10.11. In terms of profitability, RPRX's ROE is +0.12%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, RPRX is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check IPXL's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
RPRX vs OREX Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, OREX has a market cap of 0. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas OREX's P/E ratio is -0.14. In terms of profitability, RPRX's ROE is +0.12%, compared to OREX's ROE of -0.54%. Regarding short-term risk, RPRX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
RPRX vs POZN Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, POZN has a market cap of 0. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas POZN's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to POZN's ROE of +0.61%. Regarding short-term risk, RPRX is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check POZN's competition here
Shire plc (NASDAQ: SHPG)
RPRX vs SHPG Comparison October 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 24.9B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, RPRX is priced at $56.93 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 10.71, whereas SHPG's P/E ratio is 11.35. In terms of profitability, RPRX's ROE is +0.12%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, RPRX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check SHPG's competition here